紫杉醇联合洛铂治疗宫颈癌的疗效以及对患者血清FGFR4、SCCA、Spondin-2水平的影响  

Efficacy of paclitaxel combined with lobaplatin chemotherapy on cervical cancer and its effect on serum FGFR4,SCCA and Spondin-2 levels

作　　者：钱江 宋文灿[1] 鲍瑜[1] 朱立健 张建华 QIAN Jiang;SONG Wen-can;BAO Yu(Department of Oncology,Chizhou People's Hospital,Chizhou Anhui 247100,China)

机构地区：[1]池州市人民医院肿瘤科,安徽池州247100

出　　处：《临床和实验医学杂志》2022年第10期1085-1088,共4页Journal of Clinical and Experimental Medicine

基　　金：安徽省自然科学基金(编号:1408085MG146)。

摘　　要：目的探讨紫杉醇联合洛铂化疗方案治疗宫颈癌的疗效以及对患者血清成纤维细胞生长因子受体4(FGFR4)、鳞状细胞癌抗原(SCCA)、脊椎蛋白2(Spondin-2)水平的影响。方法回顾性分析2018年6月至2021年10月池州市人民医院收治的62例宫颈癌患者,根据不同治疗方案将其分为研究组(n=33)和对照组(n=29)。对照组给予紫杉醇联合顺铂化疗方案,研究组给予紫杉醇联合洛铂方案,观察两组的临床疗效、血清FGFR4、SCCA、Spondin-2水平和不良反应。结果化疗后,研究组总缓解率为84.85%,高于对照组(62.07%),差异有统计学意义(P<0.05);研究组总有效率为100%,稍高于对照组(96.55%),但差异无统计学意义(P>0.05)。化疗前,两组FGFR4、SCCA、Spondin-2水平比较,差异均无统计意义(P>0.05);化疗后,研究组FGFR4、SCCA、Spondin-2水平为(154.79±43.26)pg/mL、(3.15±0.32)ng/mL、(13.16±3.45)μg/L,均低于对照组[(198.72±62.55)pg/mL、(5.26±0.62)ng/mL、(17.49±5.74)μg/L],差异均有统计学意义(P<0.05)。在化疗期间,两组均发生了白细胞降低等骨髓抑制和呕吐、腹泻等胃肠道不良反应。两组血小板和血红蛋白下降、肝功能损害、恶心呕吐等发生率差异无统计学意义(P>0.05),研究组白细胞降低的发生率高于对照组,腹泻、肾损伤以及周围神经炎等不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论紫杉醇联合洛铂化疗方案对宫颈癌患者的具有良好的疗效,对FGFR4、SCCA和Spondin-2的调节作用较强,且肾毒性、神经毒性和胃肠道反应较小,能够改善患者生存质量。Objective To investigate the efficacy of paclitaxel combined with lobaplatin chemotherapy on cervical cancer and its effect on serum fibroblast growth factor receptor 4(FGFR4),squamous cell carcinoma antigen(SCCA)and spinal protein 2(Spondin-2).Methods Sixty-two patients with cervical cancer in Chizhou People's Hospital from June 2018 to October 2021 were retrospectively analyzed.Patients were divided into two groups according to different treatment schemes.Control group(n=29)received paclitaxel combined with cisplatin chemotherapy,while study group(n=33)received paclitaxel combined with lobaplatin chemotherapy.The clinical efficacy,serum FGFR4,SCCA,spondin-2 levels,toxic and side effects were observed.Results After chemotherapy,the total response rate was 84.85%in study group,which was significantly higher than in control group(62.07%),the difference was statistically significant(P<0.05).The total effective rate of the study group was 100%,slightly higher than that of the control group(96.55%),but the difference was not statistically significant(P>0.05).Before chemotherapy,there was no significant difference in the levels of FGFR4,SCCA and Spondin-2 between the two groups(P>0.05);after chemotherapy,the levels of FGFR4,SCCA and Spondin-2 in the study group were(154.79±43.26)pg/mL,(3.15±0.32)ng/mL,and(13.16±3.45)μg/L,which were all lower than those in the control group[(198.72±62.55)pg/mL,(5.26±0.62)ng/mL,(17.49±5.74)μg/L],the differences were statistically significant(P<0.05).During chemotherapy,bone marrow suppression such as leukopenia and gastrointestinal adverse reactions such as vomiting and diarrhea occurred in both groups.The incidence of leukopenia in the study group was higher than that in the control group,and the incidences of adverse reactions such as diarrhea,kidney injury and peripheral neuritis were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion The paclitaxel combined with lobaplatin chemotherapy regimen is highly effective in cervic

关 键 词：宫颈癌 洛铂 紫杉醇 成纤维细胞生长因子受体4 鳞状细胞癌抗原 

分 类 号：R737.33[医药卫生—肿瘤]